New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio

NEXT STORY
Mereo BioPharma Group Plc (“Mereo” or the “Company” or the “Group”) Preliminary Results for the Year Ended December 31, 2018 — Strong Operational Progress
PREV STORY
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

ROCKVILLE, Md., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a ...

author_avatar
NASDAQ Market News

Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

Phase 1 Study of PARP Inhibitor 2X-121 Selected as Oral Presentation June 1, 2018HOERSHOLM, ...

author_avatar
NASDAQ Market News

Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia

EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson ...

author_avatar
NASDAQ Market News